Core Viewpoint - The stock market experienced fluctuations, particularly in the pharmaceutical sector, but the company's fundamentals and long-term industry trends remain positive [1][2] Group 1: Stock Performance - On June 17, the Hong Kong stock market indices showed a downward trend, with the Hang Seng Index falling by 0.34%, the Hang Seng China Enterprises Index down by 0.4%, and the Hang Seng Tech Index decreasing by 0.15% [1] - Pharmaceutical stocks generally retreated, with the company, Yaoshi Bang (9885.HK), dropping by 6.31% to close at 10.4 HKD [1] Group 2: Company Actions - In response to stock price volatility, the company has been actively repurchasing shares and increasing executive holdings to stabilize market expectations [1] - On June 17, the company repurchased 100,000 shares at a total cost of approximately 1.03 million HKD, averaging 10.31 HKD per share [1] - Since initiating a billion HKD repurchase plan on May 7, the company has repurchased a total of 5.53 million shares, with a total repurchase amount exceeding 43.34 million HKD [1] - Executive Director Chen Fei also increased his holdings by 100,000 shares on June 17, bringing the total to over 900,000 shares, reflecting management's confidence in the company's future [1] Group 3: Financial Performance - The company has released positive signals this year, achieving its first annual profit in 2024, with a net profit of 157 million HKD, representing a year-on-year increase of 20.1% [1] - High-margin business growth has accelerated, with the transaction scale of the brand's first-push business reaching 717 million HKD from January to April, a year-on-year increase of 108.1% [1] - The company's proprietary brand business reached 560 million HKD, showing a significant year-on-year growth of 532.3%, indicating the formation of new growth momentum [1] Group 4: Industry Trends - The company is adapting to future pharmacy industry upgrades by entering the fields of pharmaceutical robotics and AI models [2] - In June, the company formed a strategic partnership with leading collaborative robotics firm, Yuejiang Technology, to explore high-value-added business opportunities in new retail scenarios through pharmaceutical collaborative robots, AI models, and drug IoT technologies [2] - Industry experts believe that the recent decline in the pharmaceutical sector is more related to technical adjustments following profit-taking rather than direct impacts from industrial policies or significant fundamental changes [2]

Core Viewpoint - The company, Yaoshi Bang, has initiated a share buyback plan of up to HKD 100 million, signaling strong market confidence and a commitment to enhancing shareholder value [1][3][8]. Group 1: Share Buyback and Management Actions - The company announced a share buyback plan to utilize up to HKD 100 million by October 31, 2025, and has already repurchased 3.707 million shares since the announcement, with a total expenditure exceeding HKD 27.74 million [1][3]. - Executive director Chen Fei increased his stake by purchasing 500,000 shares in April and an additional 100,000 shares on May 15 [2]. Group 2: Financial Performance and Growth - For the year 2024, the company reported a revenue of CNY 17.904 billion, a year-on-year increase of 5.5%, significantly outperforming the industry average [4]. - The company achieved a net profit of CNY 30.01 million, marking its first full-year profit, with adjusted net profit reaching CNY 157 million, a 20.1% increase year-on-year [4][5]. - Operating cash flow remained positive at CNY 656 million, reflecting a 45% year-on-year growth, indicating strong financial health [4][6]. Group 3: Operational Efficiency and Market Position - The company has a healthy debt structure with total liabilities of CNY 4.226 billion, primarily consisting of accounts payable [6]. - The company maintains a unique cash cycle with inventory turnover days of approximately 30 days and accounts receivable turnover days close to zero, allowing for efficient cash management [6]. - As of December 2024, the company had over 827,000 registered buyers, covering 98.9% of counties and 91.2% of townships in China, with a monthly active buyer count of 433,000 and a payment rate of 92.7% [4]. Group 4: Future Growth Potential - The company is positioned for significant growth with a projected compound annual growth rate of 145% in net profit from 2024 to 2027, driven by the successful implementation of high-margin proprietary brand initiatives [8][9]. - The ongoing optimization of grassroots medical resource allocation in China is expected to further enhance the company's growth prospects, as it stands to benefit from increased demand in the pharmaceutical procurement sector [9].